Business Context and Reporting Period
Corvus Pharmaceuticals, Inc. (CRVS), a Delaware corporation and emerging growth company, filed this Form 8-K on November 8, 2019. The report details a material definitive agreement entered into on the same date.
Key Financial Metrics
This filing does not contain standard financial performance metrics such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on a specific capital transaction.
Material Changes and Transaction Details
On November 8, 2019, the Company entered into an Exchange Agreement with entities affiliated with Biotechnology Value Fund, L.P. (the "Exchanging Stockholders"). Key terms include:
- Exchange Volume: 1,458,000 shares of common stock were exchanged for warrants to purchase an equal number of shares (1,458,000).
- Exercise Price: $0.0001 per share.
- Expiration: Ten years from the date of issuance.
- Ownership Limitation: Warrants cannot be exercised if the Exchanging Stockholders would beneficially own more than 9.99% of the Common Stock, subject to exceptions.
- Voting Rights: Holders of the Exchange Warrants do not have voting rights except as required by Delaware law.
- Registration Status: Issued without registration under the Securities Act of 1933, relying on the Section 3(a)(9) exemption.
Guidance, Outlook, and Risks
The filing contains no forward-looking guidance, management commentary on future operations, or discussion of general business risks. The document includes a standard disclaimer stating that representations and warranties in the Exchange Agreement were made solely for the benefit of the parties and should not be relied upon as accurately representing the Company's current affairs.
Investor Verification Checklist
- Verify the total number of outstanding shares to assess the potential dilution impact of the 1,458,000 warrants.
- Confirm the current beneficial ownership percentage of the Exchanging Stockholders to understand the 9.99% exercise limitation.
- Review the full text of the Exchange Agreement (Exhibit 10.1) and Form of Warrant (Exhibit 4.1) for additional covenants or adjustment mechanisms.
- Check subsequent filings for any exercises of these warrants or changes in the Company's capital structure.